Predictive Oncology (POAI) Stock Price, News & Analysis

Company Overview

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

Key Stats

• Today's Range: $0.92 to $0.96
• 50-Day Range: $0.87 to $1.48
• 52-Week Range: $0.55 to $3.06
• Volume: 30,608 shs
• Average Volume: 1.92 million shs
• Market Capitalization: $8.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Predictive Oncology Stock Analysis - MarketRank™

Predictive Oncology scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Predictive Oncology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Predictive Oncology has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Predictive Oncology are expected to grow in the coming year, from ($2.08) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Predictive Oncology is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Predictive Oncology is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Predictive Oncology has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.43% of the float of Predictive Oncology has been sold short.

Short Interest Ratio / Days to Cover

Predictive Oncology has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Predictive Oncology has recently decreased by 37.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Predictive Oncology does not currently pay a dividend.

Dividend Growth

Predictive Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.43% of the float of Predictive Oncology has been sold short.

Short Interest Ratio / Days to Cover

Predictive Oncology has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Predictive Oncology has recently decreased by 37.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for POAI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Predictive Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.44% of the stock of Predictive Oncology is held by insiders.

Percentage Held by Institutions

Only 9.04% of the stock of Predictive Oncology is held by institutions.

POAI Stock Analysis - Frequently Asked Questions

How have POAI shares performed this year?

Predictive Oncology's stock was trading at $0.82 on January 1st, 2025. Since then, POAI stock has increased by 14.3% and is now trading at $0.9370.
View the best growth stocks for 2025 here.

How were Predictive Oncology's earnings last quarter?

Predictive Oncology Inc. (NASDAQ:POAI) released its quarterly earnings results on Wednesday, May, 14th. The medical instruments supplier reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.23. The medical instruments supplier earned $0.11 million during the quarter, compared to analyst estimates of $1.50 million. Predictive Oncology had a negative trailing twelve-month return on equity of 286.30% and a negative net margin of 1,012.32%.

When did Predictive Oncology's stock split?

Predictive Oncology's stock reverse split on Monday, April 24th 2023. The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Predictive Oncology?

Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Predictive Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Predictive Oncology investors own include Ford Motor (F), Wells Fargo & Company (WFC), Zomedica (ZOM), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Bank of America (BAC) and Wayfair (W).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 6/06/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical appliances & supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:POAI
• CIK: 1446159
• Web: www.precisiontherapeutics.com
• Phone: (651) 389-4800
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.00
• High Stock Price Target: $3.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +220.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.98 million
• Net Margins: -1,012.32%
• Pretax Margin: -983.62%
• Return on Equity: -286.30%
• Return on Assets: -122.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.20
• Quick Ratio: 1.06

Sales & Book Value

• Annual Sales: $1.73 million
• Price / Sales: 4.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.04 per share
• Price / Book: 0.46

Miscellaneous

• Outstanding Shares: 8,932,000
• Free Float: 6,438,000
• Market Cap: $8.37 million
• Optionable: Not Optionable
• Beta: 1.30